WITHDRAWN: Clinical and CT imaging features of 2019 novel coronavirus disease (COVID-19)

Zhu, Ying; Liu, Yang-Li; Li, Ziping; Jianyi, Kuang; Li, Xiangmin; Yang, Y.; Feng, Shi‐Ting

doi:10.1016/j.jinf.2020.02.022

Cited by 32 publications

(37 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Common type patients mainly showed lung peripheral lesions, while severe type patients exhibited both peripheral and central lesions. This was similar with the statement of other earlier COVID-19 reports [5][6][7][9][10][11]. The main pattern of lesions was irregular in this study while circular or fan-shaped in early stage of the disease, which is a differentiation [5,12].…”

Section: Discussionsupporting

confidence: 93%

“…Chest computed tomography (CT) provides us a powerful noninvasive mean for the diagnosis and monitoring for COVID-19. Ground glass opacity (GGO) and consolidative opacity involving bilateral and peripheral lung were CT hallmarks of COVID-19 pneumonia [3][4][5][6][7][8]. It has been reported that CT manifestations vary depending on the infection time course [8].…”

Section: At Present Etiological Examinations Including Reverse Tranmentioning

confidence: 99%

See 1 more Smart Citation

CT features of COVID-19 patients with two consecutive negative RT-PCR tests after treatment

Tang

Chen

et al. 2020

Preprint

View full text Add to dashboard Cite

Purpose: The objective of this study is to expound the CT features of COVID-19 patients whose nucleic acid tests converted to negative after treatment.Materials and Methods: We retrospectively reviewed 46 COVID-19 patients with two consecutive negative RT-PCR tests after treatment. The cases were divided into moderate group and severe/critical group according to disease severity. Clinical and CT scanning data were collected. CT signs of pulmonary lesions and the score of long involvement were expounded.Results: 39 moderate cases and 7 severe/critical cases were included. All moderate patients showed peripheral lesions while severe/critical cases exhibited both central and peripheral lesions with all lobes involvement. Ground glass opacity (GGO) and mixed GGO were observed. Aberrant pulmonary interstitium manifested as reticular and thin linear pattern. Thickened blood vessels and pleural thickening were found. Pulmonary fibrosis, annular thickening of the bronchial wall, bronchiectasis, air bronchogram and small amount of bilateral pleural effusion were observed in severe/critical patients. The severe/critical group showed higher CT score of involvement.Conclusions: Pulmonary lesions persisted even after twice consecutive nucleic acid tests converted to negative. We strongly recommended regular follow-up of CT scans after nucleic acid tests conversion. Evaluation of complete remission should base on chest CT.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: At Present Etiological Examinations Including Reverse Tranmentioning

confidence: 99%

CT features of COVID-19 patients with two consecutive negative RT-PCR tests after treatment

Tang

Chen

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Furthermore, the mean time from presentation of symptoms to seeking medical advice is 5.8 days, and to hospital admission is 12.5 days (4). The stages of the disease from onset of symptoms has been classified based on non-contrast enhanced chest computed tomography (CT) findings and can be divided into early (0-4 days), progressive (5-8 days), peak (9-13 days), and absorption stage (≥14 days) (18). Early stage disease consisted of subpleural ground glass opacities (GGO) located in the lower lung lobes.…”

Section: Course Of Diseasementioning

confidence: 99%

Evidence based management guideline for the COVID-19 pandemic - Review article

Nicola

O’Neill

Sohrabi

et al. 2020

International Journal of Surgery

368

306

View full text Add to dashboard Cite

COVID-19 has now been declared a pandemic. To date, COVID-19 has affected over 944,181 people worldwide, resulting in over 47,312 reported deaths. Numerous preventative strategies and non-pharmaceutical interventions have been employed to mitigate the spread of disease including careful infection control, the isolation of patients, and social distancing. Management is predominantly focused on the provision of supportive care, with oxygen therapy representing the major treatment intervention. Medical therapy involving corticosteroids and antivirals have also been encouraged as part of critical management schemes. However, there is at present no specific antiviral recommended for the treatment of COVID-19, and no vaccine is currently available. Despite the strategic implementation of these measures, the number of new reported cases continues to rise at a profoundly alarming rate. As new findings emerge, there is an urgent need for up-to-date management guidelines. In response to this call, we review what is currently known regarding the management of COVID-19, and offer an evidence-based review of current practice.

show abstract

“…COVID-19 pneumonia usually presents with peripheral distribution and is often associated with reticular pattern and vascular thickening. Pleural effusion and lymphadenopathies could be observed but are more common in NON-COVID pneumonia [11][12][13].…”

Section: Covid-19 Pneumoniamentioning

confidence: 99%

COVID-19 pneumonia and immune-related pneumonitis: critical issues on differential diagnosis, potential interactions, and management

Russano

Citarella

Napolitano

et al. 2020

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

Introduction: The COVID-19 pandemic occurred amid the cancer immunotherapy revolution. Immune checkpoint inhibitors (ICIs) have become the standard of care for several solid cancers and are associated with peculiar toxicities, including pneumonitis which has similar features to COVID-19 pneumonia. Areas covered: We summarize the main hallmarks of lung injury induced by ICIs and severe acute respiratory syndrome coronavirus 2 and discuss the critical aspects for differential diagnosis and management. Symptoms and radiological findings are often similar; conversely, treatments are quite different. Furthermore, we focus on potential interactions generating hypotheses that need confirmatory studies. Expert opinion: All cancer patients treated with immunotherapy should receive screening for SARS-CoV-2. This would improve the diagnosis and management of pneumonia and guide therapeutic choices. Furthermore, clinicians could estimate the risk/benefit of continuing ICI treatment in COVID-19 positive patients. Temporary withdrawal of the immunotherapy treatment pending resolution of viral infection may be a reasonable option in long-responders patients.

show abstract

WITHDRAWN: Clinical and CT imaging features of 2019 novel coronavirus disease (COVID-19)

Cited by 32 publications

References 7 publications

CT features of COVID-19 patients with two consecutive negative RT-PCR tests after treatment

CT features of COVID-19 patients with two consecutive negative RT-PCR tests after treatment

Evidence based management guideline for the COVID-19 pandemic - Review article

COVID-19 pneumonia and immune-related pneumonitis: critical issues on differential diagnosis, potential interactions, and management

Contact Info

Product

Resources

About